Halozyme Therapeutics (NASDAQ:HALO) Share Price Breaks Below 50 Day Moving Average - Here's Why

Key Points

• Halozyme shares fell below their 50-day moving average, trading at $103.63 versus the $115.19 average, amid a reported 15.7% decline.
• Despite the weak share reaction, Q3 revenue rose 39% to about $493 million and adjusted EPS of $2.39 topped estimates; the company also raised its 2026 guidance. Investors may be weighing whether results met high expectations, while a Merck patent dispute remains a focus.
• Other potential positives include FDA approval of a treatment using Halozyme’s ENHANZE technology and the company’s view that Medicare drug-price negotiations should have zero to minimal royalty impact through at least 2035. Analyst views vary, though MarketBeat’s consensus rating is “Moderate Buy.”

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report)'s share price crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $115.19 and traded as low as $102.52. Halozyme Therapeutics shares last traded at $103.63, with a volume of 6,162,578 shares.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Wall Street Analyst Weigh In

Several research analysts recently issued reports on HALO shares. HC Wainwright lifted their target price on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the company a "market outperform" rating in a research report on Friday. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Tuesday. Zacks Research raised shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 13th. Finally, Weiss Ratings raised Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $106.09.

Halozyme Therapeutics Trading Down 15.7%

The company has a 50-day moving average price of $115.19 and a 200-day moving average price of $84.73. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a market capitalization of $11.76 billion, a price-to-earnings ratio of 26.37, a P/E/G ratio of 0.49 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.09. The business had revenue of $492.97 million for the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics's quarterly revenue was up 39.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 8.32 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company's stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 18,996 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the transaction, the director owned 58,839 shares of the company's stock, valued at approximately $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock valued at $13,538,046 in the last ninety days. Corporate insiders own 2.50% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of large investors have recently made changes to their positions in HALO. Allworth Financial LP raised its holdings in Halozyme Therapeutics by 3.5% during the third quarter. Allworth Financial LP now owns 38,995 shares of the biopharmaceutical company's stock worth $4,305,000 after purchasing an additional 1,331 shares in the last quarter. R Squared Ltd bought a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $225,000. Fifth Third Bancorp increased its holdings in Halozyme Therapeutics by 52.3% during the 3rd quarter. Fifth Third Bancorp now owns 145,756 shares of the biopharmaceutical company's stock valued at $16,091,000 after purchasing an additional 50,075 shares in the last quarter. Maryland State Retirement & Pension System boosted its position in shares of Halozyme Therapeutics by 20.9% during the third quarter. Maryland State Retirement & Pension System now owns 7,382 shares of the biopharmaceutical company's stock worth $815,000 after purchasing an additional 1,275 shares in the last quarter. Finally, Ritholtz Wealth Management grew its stake in shares of Halozyme Therapeutics by 17.3% in the third quarter. Ritholtz Wealth Management now owns 6,570 shares of the biopharmaceutical company's stock valued at $725,000 after buying an additional 971 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.